The US Food and Drug Administration (FDA) issued final guidance on 2 November 2026 telling manufacturers of cell and gene therapies to build potency assurance into every stage of a product's life, rather than relying on a final lab test alone. The guidance, titled Potency Assurance for Cellular and Gene Therapy Products, replaces the agency's 2011 guidance on potency testing and applies to treatments for serious and often life-threatening conditions, including cancers and rare diseases.
What the Guidance Asks Manufacturers to Do
At the centre of the document is the Potency Assurance Strategy. Under it, a manufacturer should test and verify, before a product reaches a patient, that every batch meets a defined standard of potency, meaning the product can do what it is supposed to do in the body. That strategy should run from early-phase investigational new drug submissions through biologics licence application approval and continued checks after approval.
The guidance covers the practical points where potency can drift. It discusses controls for variability in raw materials, testing during manufacturing, and lab tests that confirm each batch is biologically active in a way that matches its intended effect. It also addresses products that are harder to handle than most medicines, including therapies with short shelf lives, viral vector gene therapies, and patient-specific therapies made for one person at a time.
From a 2023 Draft to a Final Document
The final guidance closes a process that began with a draft in December 2023, filed under docket FDA-2023-D-4299. The Regulatory Affairs Professionals Society reported that the final version adds advice on folding potency assurance into a company's existing quality systems, more guidance on risk assessments, recommendations on engaging with regulators, and new examples and clearer wording throughout.
Two points matter for readers who are not manufacturers. First, like all FDA guidance, the document sets out the agency's current thinking and is not itself legally binding, though manufacturers are still expected by law to verify that their products work as intended from approval through post-approval monitoring. Second, the guidance does not change any approved product or recall any therapy. It changes how sponsors are expected to show, batch by batch, that a product keeps its intended activity.
Why This Matters for Healthcare Organizations
Most clinics will never manufacture a cell or gene therapy, but a growing number now administer them or refer patients for them, and potency is the link between a promising treatment and a treatment that works as promised. A therapy that loses activity during production, storage or handling may look identical on arrival and still fail the patient. A lifecycle approach, with checks built into materials, production and release rather than bolted on at the end, gives treating teams a stronger basis for trusting the product in front of them.
The guidance also has a practical timing point. The FDA will host a webinar on 10 December 2026 to help stakeholders understand and apply it, so organisations with cell and gene therapy programmes have a clear date to put staff learning on the calendar. Questions about how a specific product's potency is assured still belong with the manufacturer and the treating team, not with a general news summary.
Analysis: Quality Assurance Moves Upstream
The shift here is one of timing. The old model treated potency mainly as a test at the end of production. The new model treats it as a property that has to be protected at each step, from the starting materials to the finished batch. That is a harder standard to meet, because it asks manufacturers to show their working across the whole process, but it is also a more honest one for products as variable as living cells and gene therapies, where a single final test can miss problems that built up earlier.
For hospitals and clinics, the value is indirect but real. Clearer expectations for manufacturers should mean fewer surprises in supply and fewer questions about whether a delivered batch will perform. The guidance will not settle every dispute about a specific product, and it creates no new legal duty on its own. What it does is give the field a shared language for the conversation between sponsors, regulators and the clinicians who ultimately give these therapies to patients.
Clinics exploring how digital tools fit into complex care pathways can look at MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote for their own practice. For related coverage, see our earlier article on FDA and CMS steps to advance gene therapies and widen Medicaid access.
Sources and References
- U.S. Food and Drug Administration — FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality, 2 November 2026: https://www.fda.gov/news-events/press-announcements/fda-provides-clarity-support-cell-and-gene-therapy-development-and-quality
- Regulatory Affairs Professionals Society — FDA finalizes cell and gene therapy potency guidance, 2 November 2026: https://www.raps.org/resource/fda-finalizes-cell-and-gene-therapy-potency-guidance.html
- BioPharma International — FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies, 3 November 2026: https://www.biopharminternational.com/view/fda-final-guidance-potency-assurance-cell-gene-therapy-products
Reporting based on the sources above, accessed 4 November 2026. The FDA press release was read directly, and the Regulatory Affairs Professionals Society and BioPharma International reports were read directly and cross-checked against it. MedClinicX did not conduct original reporting or interviews for this article. This article is for information only and is not medical advice. Corrections: contact us via https://medclinicx.com/contact